The patent encompasses methods for high content screening, including methods for cell-based detection and classification and/or identification of toxins in a test substance
Cellomics reports that the US Patent and Trademark Office (USPTO) issued it with patent 6,416,959 entitled 'A system for cell-based screening'.
The patent encompasses methods for high content screening, including methods for cell-based detection and classification and/or identification of toxins in a test substance.
Specifically, the claims include methods of measuring the localisation, distribution, structure or activity of fluorescent reporter molecules to detect the presence of a toxin in a test substance, identify the pathway that is perturbed by the toxin, and/or identify the specific toxin or group of toxins that are present in the test substance.
"Effective implementation of HCS assays for cytotoxicity assessment is rapidly becoming critical in drug discovery.
"This patent strengthens our already strong portfolio of BioApplications and reagents that, together with the rest of our powerful HCS platform, enable our users to quickly integrate cytotoxicity evaluations into their research," stated Jeffrey Haskins, vice president of assay development with cellomics.
"This patent expands Cellomics's portfolio of intellectual property in the HCS area," added Lansing Taylor, CEO. "We believe that this patent, as well as our additional patent applications on HCS assays, reagents, instrumentation, and tools for information management and cellular bioinformatics, will further Cellomics's standing as the leader in HCS"" Cellomics is pioneering the field of cellular knowledge extraction.
Its unique technology, referred to as high content screening, integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and information management systems to achieve a flexible, broadly applicable platform for users in the life sciences.
